Search - tctmd.com

Displaying 141 - 160 of 251

Sort: Relevancy | Date

News Industry News

Kona Medical Initiates Clinical Trial of Non-Invasive Therapy for Resistant Hypertension

August 27, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

Yael L. Maxwell

June 11, 2014

News Daily News

SYMPLICITY HTN-2: La Denervación Renal es Segura y Eficaz a los 3 Años

Yael L. Maxwell

June 11, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Industry News

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

May 22, 2014

News Conference News EuroPCR 2014

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Yael L. Maxwell

May 22, 2014

News Industry News

Medtronic Announces CE Mark and Launch of NC Euphora(TM) Coronary Balloon

May 20, 2014

News Daily News

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

May 12, 2014

News Daily News

Renal Denervation Shows Promise in Patients Refractory to Stenting

L.A. McKeown

May 02, 2014

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

Global SYMPLICITY Registry Still Shows Positive Results for Renal Denervation

Yael L. Maxwell

March 30, 2014

News Conference News ACC 2014

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Yael L. Maxwell

March 29, 2014

News Industry News

Boston Scientific Announces Schedule for Presentations at American College of Cardiology 2014

March 27, 2014

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2013

Jason Kahn

January 27, 2014

News Industry News

Covidien to Exit OneShot™ Renal Denervation Program

January 20, 2014

News Industry News

Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint

January 08, 2014

News Industry News

Medtronic Randomizes First Patients in SYMPLICITY HTN-4, the First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension

December 16, 2013

Advertisement

Kona Medical Initiates Clinical Trial of Non-Invasive Therapy for Resistant Hypertension

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

SYMPLICITY HTN-2: Renal Denervation Safe, Effective at 3 Years

SYMPLICITY HTN-2: La Denervación Renal es Segura y Eficaz a los 3 Años

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Medtronic Announces CE Mark and Launch of NC Euphora(TM) Coronary Balloon

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

Renal Denervation Shows Promise in Patients Refractory to Stenting

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Global SYMPLICITY Registry Still Shows Positive Results for Renal Denervation

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Boston Scientific Announces Schedule for Presentations at American College of Cardiology 2014

TCTMD’s Top 10 Most Popular News Stories for 2013

Covidien to Exit OneShot™ Renal Denervation Program

Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint

Medtronic Randomizes First Patients in SYMPLICITY HTN-4, the First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content